FDA.reportPublic FDA data

glecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet

RxCUI
2557906
RxNorm name
glecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet
Display name
glecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet
Full name
glecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MavyretGLECAPREVIR AND PIBRENTASVIRAbbVie Inc.7bf99777-0401-9095-8645-16c6e907fcc02025-06-25Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2557906

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
7bf99777-0401-9095-8645-16c6e907fcc0glecaprevir 50 MG / pibrentasvir 20 MG per packet Oral Pellet [PSN] · glecaprevir 50 MG / pibrentasvir 20 MG Oral Pellet [SCD]2200These highlights do not include all the information needed to use MAVYRET safely and effectively. See full prescribing information for MAVYRET. MAVYRET ® (glecaprevir and pibr entasvir) tablets, for oral use MAVYRET ® (glecaprevir and pibrentasvir) oral pellets Initial U.S. Approval: 201720250610